Third Harmonic Bio, Inc. (THRD – Research Report) received a Buy rating and price target from LifeSci Capital analyst Sam Slutsky today. The company’s shares closed today at $5.60.
According to TipRanks, Slutsky is a 4-star analyst with an average return of 4.9% and a 45.63% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Cogent Biosciences, Immunovant, and Rain Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Third Harmonic Bio, Inc. with a $5.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $24.60 and a one-year low of $3.75. Currently, Third Harmonic Bio, Inc. has an average volume of 62.46K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company’s lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
Read More on THRD:
